Taro Penalties Exceed $400m As It Admits Fixing Prices With Sandoz

Criminal Penalty And Civil Damages Announced

In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.

Department of Justice
Taro has agreed to cooperate fully with the DoJ Antitrust Division’s ongoing criminal investigation • Source: Shutterstock

Taro Pharmaceutical Industries’ US subsidiary has become the fifth pharmaceutical company to admit that it conspired to fix the prices of generic medicines, agreeing to pay a $205.7m criminal penalty as part of a three-year deferred prosecution agreement with the US Department of Justice.

The Sun Pharma affiliate – which admitted that its sales affected by the charged conspiracies “exceeded $500m” – is also...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business